Safety and Tolerability of Angiotensin Receptor-Neprilysin Inhibitor Initiation in High-Risk Acute Myocardial Infarction Relative to Care Setting: A Subgroup Analysis of the PARADISE-MI Trial-Reference-Cited by-同舟云学术

Safety and Tolerability of Angiotensin Receptor-Neprilysin Inhibitor Initiation in High-Risk Acute Myocardial Infarction Relative to Care Setting: A Subgroup Analysis of the PARADISE-MI Trial

Published:2024-07 Issue:7 Volume:17 Page:
ISSN:1941-3289
Container-title:Circulation: Heart Failure
language:en
Short-container-title:Circ: Heart Failure

Author:

De Pasquale Carmine G.¹²,Claggett Brian³^ORCID,Jering Karola³^ORCID,McMurray John J.V.⁴^ORCID,Mann Douglas⁵^ORCID,Miao Zi Michael³^ORCID,Granger Christopher B.⁶^ORCID,Køber Lars⁷^ORCID,Maggioni Aldo P.⁸^ORCID,Rouleau Jean-Lucien⁹^ORCID,Solomon Scott D.³^ORCID,Steg Philippe Gabriel¹⁰^ORCID,van der Meer Peter¹¹^ORCID,Braunwald Eugene¹²^ORCID,Pfeffer Marc A.³^ORCID

Affiliation:

1. Cardiology Department, Flinders Medical Centre, Adelaide, SA, Australia (C.G.D.P.).

2. Flinders University, Adelaide, SA, Australia (C.G.D.P.).

3. Cardiovascular Division (B.C., K.J., Z.M.M., S.D.S., M.A.P.), Brigham and Women’s Hospital and Harvard Medical School, Boston, MA.

4. British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Scotland (J.J.V.M.).

5. Washington University Medical Center, St. Louis, MO (D.M.).

6. Duke University Medical Center, Durham, NC (C.B.G.).

7. Rigshospitalet, Blegdamsvej, Copenhagen, Denmark (L.K.).

8. ANMCO Research Center, Heart Care Foundation, Florence, Italy (A.P.M.).

9. Montréal Heart Institute, University of Montréal, Quebec, QC, Canada (J.-L.R.).

10. Université Paris-Cité, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, INSERM U1148, French Alliance for Cardiovascular Trials, France (P.G.S.).

11. Department of Cardiology, University Medical Center Groningen, University of Groningen, the Netherlands (P.v.d.M.).

12. TIMI Study Group, Cardiovascular Division (E.B.), Brigham and Women’s Hospital and Harvard Medical School, Boston, MA.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference5 articles.

1. Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

2. Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction

3. Angiotensin Receptor–Neprilysin Inhibition in Acute Myocardial Infarction

4. Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE‐MI): design and baseline characteristics

5. Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure